Navigation Links
Regulus Reports Third Quarter 2013 Financial Results and Recent Highlights
Date:11/13/2013

he three months ended September 30, 2013, compared to $1.1 million for the same period in 2012.  The increase was primarily attributable to additional headcount and incremental operating costs associated with being a public company.

Net loss in the three months ended September 30, 2013 included a non-cash gain of $0.7 million from the change in value of the amended and restated convertible promissory note originally issued to GlaxoSmithKline plc in 2010, with such change in value attributable to a decrease in value of the common stock of the Company during the quarter.  Net loss in the three months ended September 30, 2012 included a non-cash charge of $1.7 million resulting from a loss on extinguishment of debt associated with the modification of the convertible promissory note, and a $0.3 million non-cash charge from the increase in value of the common stock of the Company during the quarter. 

Conference Call & Webcast InformationRegulus will host a conference call and webcast at 5:00 p.m. Eastern Standard Time today to discuss its third quarter 2013 financial results and recent corporate highlights. A live webcast of the call will be available online at www.regulusrx.com. To access the call, please dial (877) 257-8599 (domestic) or (970) 315-0459 (international) and refer to conference ID 93095033.  To access the telephone replay of the call, dial (855) 859-2056 (domestic) or (404) 537-3406 (international), passcode 93095033. The webcast and telephone replay will be archived on the company's website following the call. 

About the 'Road to the Clinic' Strategy in 2013 Launched in February 2013, the 'Road to the Clinic' Strategy outlines certain corporate goals that seek to advance our microRNA therapeutic pipeline toward the clinic this year. Specifically, Regulus set the goal of nominating two microRNA cand
'/>"/>

SOURCE Regulus Therapeutics Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Regulus Presents Positive Preclinical Data Demonstrating that microRNA-21 Plays an Important Role in Alport Syndrome
2. Regulus Announces Timing for Third Quarter 2013 Financial Results Webcast and Conference Call
3. Regulus Announces Significant Progress in Strategic Alliance with AstraZeneca and Selection of a New Pre-Clinically Validated microRNA Oncology Target
4. Regulus Reports Second Quarter 2013 Financial Results and Recent Highlights
5. Regulus Announces Timing for Second Quarter 2013 Financial Results Webcast and Conference Call
6. Regulus Names Stelios Papadopoulos, Ph.D. as Chairman of its Board of Directors
7. Regulus to Present at Deutsche Bank 38th Annual Healthcare Conference
8. Regulus Provides Update on Road to the Clinic Strategy and Reports First Quarter 2013 Financial Results and Recent Highlights
9. Regulus Announces Timing for First Quarter 2013 Financial Results Webcast and Conference Call
10. Regulus Appoints William H. Rastetter, Ph.D. to its Board of Directors
11. Regulus to Present at Future Leaders in the Biotech Industry Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... 23, 2015  Mallinckrodt plc (NYSE: MNK ) ... a share repurchase program. The open-ended authorization permits the ... plc ordinary shares. "Funding additional initiatives ... as we continue to pursue a range of focused ...
(Date:1/22/2015)... 2015  ViewRay™, a privately held medical device company, announced ... agreement with ITOCHU Corporation (Tokyo Stock Exchange TYO: 8001) ... treatment of cancer in Japan . ... first and only MRI-guided radiation therapy system that images ...
(Date:1/22/2015)... Jan. 22, 2015 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ("Pivotal" ... on Omega-3 therapies for cardiovascular disease and overall health is ... accomplishments in 2014 and its outlook for 2015 from the ... Shareholders, We would like to take this opportunity ...
Breaking Medicine Technology:Mallinckrodt plc Announces Share Repurchase Program 2Mallinckrodt plc Announces Share Repurchase Program 3Mallinckrodt plc Announces Share Repurchase Program 4ITOCHU Named the Exclusive Distributor for ViewRay's MRI-Guided Radiation Therapy System in Japan 2Pivotal Therapeutics: Year in Review and CEO Update 2Pivotal Therapeutics: Year in Review and CEO Update 3Pivotal Therapeutics: Year in Review and CEO Update 4Pivotal Therapeutics: Year in Review and CEO Update 5Pivotal Therapeutics: Year in Review and CEO Update 6Pivotal Therapeutics: Year in Review and CEO Update 7
... SANTA MONICA, Calif., Feb. 16, 2012 GoodRx ... prescription drug price comparison technology that provides consumers with accurate ... both a website and free iphone app ... greatly between competing pharmacies, and find discounts, free coupons and ...
... 15, 2012 Halozyme Therapeutics, Inc. (NASDAQ: HALO ... of 7,820,000 shares of its common stock, including 1,020,000 shares ... previously granted to the underwriter. All of the shares were ... $10.61 per share. The proceeds to Halozyme from this offering ...
Cached Medicine Technology:GoodRx™ Brings Price Transparency to Prescription Drugs 2GoodRx™ Brings Price Transparency to Prescription Drugs 3GoodRx™ Brings Price Transparency to Prescription Drugs 4Halozyme Announces Exercise in Full of Over-Allotment Option and Completion of Public Offering of Stock 2Halozyme Announces Exercise in Full of Over-Allotment Option and Completion of Public Offering of Stock 3
(Date:1/22/2015)... Juvent Sports ( http://www.juventsports.com ) and David Leadbetter ... to bestow a Juvent Sports Achievement award upon an ... The award commemorated and congratulated McKitrick for her record ... her first amateur tournament in 1979 and most recently ...
(Date:1/22/2015)... January 22, 2015 For over 20 years, Dr. ... Oceanside and Vista area has treated just about every type ... injury circumstances. And for those same twenty-plus years, the team ... all those injuries with the best possible doctor. With ...
(Date:1/22/2015)... Yesterday, Senator Holly Mitchell (D-Los ... Olsen (R-Modesto) were honored by the California Healthcare ... biomedical science, medical device and pharmaceutical innovation in ... “2014 Life Sciences Champion” award from CHI President ...
(Date:1/22/2015)... WASHINGTON, DC (PRWEB) January 22, 2015 ... conditions in vulnerable communities and cause financial distress to ... report by analysts at Howard University’s Center on Race ... of dollars in economic activity, payday loans at the ...
(Date:1/22/2015)... released a new blog post presenting a list of vehicles that ... , Some types of vehicles cannot be covered under an ordinary ... to see if their vehicle qualifies for auto insurance coverage. ... cars that cannot be covered by a plan. Clients have little ...
Breaking Medicine News(10 mins):Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 3Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2Health News:Some Vehicles Cannot Be Covered By An Auto Insurance Policy! 2
... support proteomic test as a predictor of overall survival ... on VeriStrat, a blood-based, proteomic test currently used for ... be presented by Christine Chung, MD, Assistant Professor of ... 1st at the 45th Annual Meeting of the American ...
... Medical Waste Processing PermitSUN VALLEY, Calif., May 14 ... Sun Valley, California, the owner and worldwide patent ... System(TM), today announced its latest medical waste processing ... on 2.7 acres at 2020 Montcalm Street in ...
... ImQuest Bio and Arisyn jointly presented important new results ... hepatitis C virus (HCV) replication, at the 13th ISVHLD meeting ... the ability of PG301029 to potently suppress the replication of ... of antiviral action through the selection of a replicon resistant ...
... storage system extends PreXion3D image scans to network ... ( www.Prexion.com ), a leader in ... availability of DataServer/PX, a DICOM-conformant, massive storage system ... that has accumulated over time through the use ...
... Genetics, Inc. (NYSE Amex: ILI ) today ... ended March 31, 2009."In the first quarter we met ... on a very important research collaboration with a biotech ... and obesity at two important scientific conferences, established a ...
... Griffin, group president, health plans, Medco Health Solutions, Inc. ... the Deutsche Bank 34th Annual Health Care Conference in ... InterContinental Boston, will begin at 8:50 a.m. EDT. ... to attend.The presentation may be heard live via a ...
Cached Medicine News:Health News:May 14, 2009: Biodesix Announces VeriStrat(R) Data in Head and Neck Cancer to be Presented at ASCO 2Health News:May 14, 2009: Biodesix Announces VeriStrat(R) Data in Head and Neck Cancer to be Presented at ASCO 3Health News:Back Home Again in Indiana 2Health News:ImQuest BioSciences and Arisyn Therapeutics Introduce Novel New HCV Therapeutic Agent at Hepatitis Conference 2Health News:PreXion Adds a Fast, High-Volume Data Storage and Archiving System for Use With Its PreXion3D CBCT X-ray System 2Health News:Interleukin Genetics Reports First Quarter 2009 Financial Results 2Health News:Interleukin Genetics Reports First Quarter 2009 Financial Results 3Health News:Interleukin Genetics Reports First Quarter 2009 Financial Results 4Health News:Interleukin Genetics Reports First Quarter 2009 Financial Results 5Health News:Interleukin Genetics Reports First Quarter 2009 Financial Results 6Health News:Medco to Present at the Deutsche Bank 34th Annual Health Care Conference 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: